Clinical hematology international最新文献

{"title":"Social media in medicine: a personal perspective about opportunities, challenges, and best practice.","authors":"Mohamad Mohty, Bipin Savani","doi":"10.46989/001c.125931","DOIUrl":"https://doi.org/10.46989/001c.125931","url":null,"abstract":"","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"114-116"},"PeriodicalIF":0.0,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11589961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.","authors":"Michelle Kenyon, Sarah Jayne Liptrott, Annika Kisch, Jarl Mooyaart, Brian Piepenbroek, Daphna Hutt, Isabel Salcedo, Annalisa Ruggeri, Cristian Chabannon, Rose Ellard, John Murray","doi":"10.46989/001c.124593","DOIUrl":"10.46989/001c.124593","url":null,"abstract":"<p><strong>Background: </strong>Advanced Therapy Medicinal Products (ATMPs) for human use have advanced globally with the rapid adoption of Chimeric Antigen Receptor T-cell (CAR-T) therapies in haemato-oncology. CAR-T cell therapy and ATMPs have unique, significant acute and chronic toxicities, and appropriate patient care is crucial. Significant challenges, including the need for nurse education and training, accompany optimal patient success and benefits.</p><p><strong>Objectives: </strong>This study aimed to describe nurses' training needs in relation to ATMP management and patient care.</p><p><strong>Methods: </strong>A cross-sectional online survey was performed by the European Society for Blood and Marrow Transplantation, based on a previously tested questionnaire developed in the UK.</p><p><strong>Findings: </strong>109 complete responses from 86 different centers from 24 countries were returned (1207 distributed). Over 1/3 reported experience delivering licensed ATMPs (CAR-T). High-priority training areas included a general introduction to ATMPs, toxicity management, product-specific information, and regulatory frameworks for ATMPs. A clear need for ATMP-specific training exists and is regarded as important. Training prior to implementation is key and should be supported by ongoing competency maintenance. Counseling, patient support, and long-term follow-up are identified for future training and opportunities for nurse experience sharing in this rapidly evolving field.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"104-113"},"PeriodicalIF":0.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Untangling the clonal architecture in a case of acute myeloid leukaemia with multiple cytogenetically unrelated clones.","authors":"Helen Cashman, Andrew J Wilson, Ke Xu, Elisabeth Nacheva, Robert Baker, Rajeev Gupta","doi":"10.46989/001c.124931","DOIUrl":"10.46989/001c.124931","url":null,"abstract":"","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"100-103"},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report.","authors":"Khushnuma Mullanfiroze, Charlotte Jones, David Williams, Matias Vieira, Ashutosh Wechalekar, Xenofon Papanikolaou, Rakesh Popat, Charalampia Kyriakou, Ke Xu","doi":"10.46989/001c.124664","DOIUrl":"10.46989/001c.124664","url":null,"abstract":"<p><p>not included as this is letter to the editor.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"89-92"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514130/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of approved CAR-T products and utility in clinical practice.","authors":"Shakthi T Bhaskar, Bhagirathbhai Dholaria, Bipin N Savani, Salyka Sengsayadeth, Olalekan Oluwole","doi":"10.46989/001c.124277","DOIUrl":"10.46989/001c.124277","url":null,"abstract":"","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"93-99"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.","authors":"Rahul Shah, Danielle Murphy, Melissa Logue, James Jerkins, Andrew Jallouk, Kassim Adetola, Olalekan Oluwole, Reena Jayani, Eden Biltibo, Tae K Kim, Salyka Sengsayadeth, Wichai Chinratanalab, Carrie Kitko, Bipin Savani, Bhagirathbhai Dholaria","doi":"10.46989/001c.124926","DOIUrl":"10.46989/001c.124926","url":null,"abstract":"<p><p>Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor. While the mainstay of treatment has remained systemic immunosuppression with glucocorticoids, progress has been made within the last few years with approvals of three oral agents to treat steroid-refractory cGVHD: ibrutinib, ruxolitinib, and belumosudil. Iatrogenesis contributes a significant portion of the morbidity experienced by patients with cGVHD, primarily from glucocorticoids. This review highlights the myriad impacts of cGVHD, including and beyond the traditional organ systems captured by the National Institutes of Health Consensus Criteria, including iatrogenic complications of long-term immunosuppression. It presents the implications of cGVHD and its treatment on cardiovascular and metabolic health, bone density, endocrine function, sexual health, and ocular and pulmonary disease and outlines a framework around the comprehensive multidisciplinary approach for its evaluation and management.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"74-88"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary GvHD: is it time to change the NIH diagnostic criteria?","authors":"Martina Canichella, Poalo de Fabritiis","doi":"10.46989/001c.124551","DOIUrl":"https://doi.org/10.46989/001c.124551","url":null,"abstract":"","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"69-73"},"PeriodicalIF":0.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delivering an impactful presentation: a practical guide.","authors":"Mohamad Mohty","doi":"10.46989/001c.124436","DOIUrl":"https://doi.org/10.46989/001c.124436","url":null,"abstract":"","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"67-68"},"PeriodicalIF":0.0,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study.","authors":"Allison C Y Tso, Wee Joo Chng, Yeow Tee Goh, Melissa G Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Sanchalika Acharyya, Kiat Hoe Ong","doi":"10.46989/001c.124362","DOIUrl":"https://doi.org/10.46989/001c.124362","url":null,"abstract":"<p><p>Singapore leads Southeast Asia in the routine use of daratumumab for multiple myeloma and other plasma cell dyscrasias. This retrospective review analyzed 112 patients who received daratumumab between 2012 and 2020. Tolerability, and efficacy based on prior lines (PL) of therapy, cytogenetic risk group, and the presence of renal impairment were presented. Infusion-related reactions occurred in 26.8% of patients. Grades 1 and 2 hematological and non-hematological adverse events were observed in 14.3% and 33.9% of patients, respectively. After a median follow-up of 16.9 months, there was no significant difference in overall response rates (ORR) (86% versus 76.3%, p = 0.082) or depth of response (≥ complete response (CR), 35.1% versus 28.9%, p = 0.469) between myeloma patients with and without renal dysfunction. Newly diagnosed and relapsed/refractory patients had an ORR of 92% and 76.3%, and a ≥ VGPR (very good partial response) rate of 80% and 55.3%, respectively. Median progression-free survival (PFS) was better for patients with 0/1 PL compared to ≥ 2 PLs (19.8 versus 6.2 months, p < 0.001), with a deeper response (≥ CR, 38.5% versus 16.7%, p = 0.033). Forty-six and a half percentage of patients had high-risk FISH abnormalities, and those with 0/1 PL had a significantly better ORR than those with ≥ 2 PLs (83.3% vsersus 47.1%, p = 0.022), achieving an ORR similar to that of the general cohort (80.2%, p = 0.905). In conclusion, positioning daratumumab in earlier lines of therapy leads to better outcomes and may mitigate the impact of high-risk FISH abnormalities.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"53-66"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.","authors":"Minoo Battiwalla, Ju-Hsien Chao, Tonya Cox, Jose Carlos Cruz, William B Donnellan, Alireza Eghtedar, Suman Kambhampati, Shahbaz Malik, Michael B Maris, Marcello Rotta, Frank T Slovick, Aravind Ramakrishnan, Vikas Bhushan, Lindsay Sears, Casey Martin, Jared Holder, Angela Junglen, Navneet Majhail, Charles F LeMaistre","doi":"10.46989/001c.124273","DOIUrl":"https://doi.org/10.46989/001c.124273","url":null,"abstract":"<p><p>The treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic or National Cancer Institute (NCI)-designated cancer centers. This was a multi-level, case-controlled study of real-world outcomes for initial AML treatment in a community-based network for 1,391 patients with AML between 2011 and 2018. We benchmarked survival within our network against the Surveillance, Epidemiology, and End Results (SEER) database. Coarsened exact matching was performed against 17,186 chemotherapy-treated patients in the SEER database. Cox proportional and accelerated failure time multivariable modeling were performed to identify patient, disease, therapy and center characteristics associated with the risk of AML mortality. Within the network, 799 patients were treated at six specialized blood cancer centers and 592 at 63 other hospitals. Patients receiving high-intensity induction at specialized centers had improved median survivals of 31 months versus 18 months [P<0.001] at non-specialized centers. Median survivals were 13 for non-specialized centers versus 10 months for SEER [P<0.001], and 18 for the entire network versus 10 months for SEER [P<0.001]. Multivariable modeling showed significant impacts from age (<i>HR</i> = 1.025), high-intensity induction therapy (<i>HR</i>= .695), diagnosis year (<i>HR</i>= .937), neighborhood income (<i>HR</i> = .997; P<0.01), higher acuity (<i>HR</i> = 1.002) and Charlson comorbidity score (<i>HR</i> = 1.117). AML treatment may be effectively delivered in the community hospital setting, with specialized centers producing better outcomes for higher intensity treatments.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"6 4","pages":"43-52"},"PeriodicalIF":0.0,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}